Corealis Pharma Inc. inaugurates new facilities in Laval Science Park
by CM Staff
This expansion, the result of an investment exceeding $10 million, extends the premises of the Quebec-based company from 33,000 to 63,000 square feet, facilitating the installation of new laboratories.
LAVAL — In the presence of Christopher Skeete, Minister for the Economy, and Christine Poirier, Laval City Councillor, Corealis Pharma Inc. inaugurated the expansion of its facilities nestled in the heart of Laval’s Biotech City. This expansion, the result of an investment exceeding $10 million, extends the premises of the Quebec-based company from 33,000 to 63,000 square feet, facilitating the installation of new laboratories.
“My co-founders and I are immensely proud today to inaugurate these state-of-the-art laboratories. These facilities will bolster our research and development capabilities for new drugs, catering to global growth and enhancing our market presence,” stated Corealis President Yves Roy.
Established in 2005 by three scientists – Yves Roy, Patrick Gosselin, and Yves Mouget – the Laval-based company is a Contract Research and Development Organizations (CRO/CDMOs). In 2022, to expedite its expansion, Corealis forged a partnership agreement with the CDPQ and Archimed a global investment firm focused on healthcare industries. With a clientele predominantly located in New England and California, alongside various other regions worldwide, the company says they recorded a notable 20% increase in sales for 2023.
“I am proud to celebrate Corealis’ success today! By supporting companies in the life sciences, a key sector of our economy, we are strengthening the international influence of Quebec’s expertise. Corealis perfectly embodies this dynamic,” declared Mr. Christopher Skeete, Minister for the Economy.
In addition to fostering its workforce expansion, the new space will reportedly enable Corealis Pharma to expedite:
- Advancements in formulation development and manufacturing of oral solid dosage forms
- Early-stage projects
- Analytical method development
- Integration of state-of-the-art analytical and formulation equipment
- The pace and scale of drug research and development
- Expanded clinical trial material manufacturing and packaging
“Corealis elevates the profile of Quebec and the city of Laval, in particular. We take immense pride in supporting the directors and employees of this esteemed company, facilitating its continued growth on our soil, thus reaffirming Biotech City as a premier destination for investment and advancement in Quebec’s life sciences landscape,” concluded Laval City Councillor Christine Poirier.
